Oncoceutics Release: ONC201 Featured In 7 Abstracts At 2015 American Association for Cancer Research Meeting

Hummelstown, PA – Oncoceutics, Inc. a drug discovery and development company targeting the most potent suppressor pathways in human cancer, along with its collaborators, has been selected to present at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held in Philadelphia. The seven abstracts selected for presentation include results of preclinical studies that continue to demonstrate the robust efficacy of ONC201, Oncoceutics’ new oncology drug, in aggressive and refractory cancers. The presentations will also further elucidate the mechanism of action that underpins ONC201’s compelling efficacy and safety profile. Clinical trials for ONC201 are currently underway.

Abstract Details:

Early integrated stress response induction of ATF4 is required for the anticancer effects of the dual Akt/ERK inhibitor and TRAIL pathway inducer ONC201/TIC10. Kline et al.
Abstract Number: 674
Presentation Time: Sunday Apr 19, 2015 1:00 PM - 5:00 PM
Session Category: Experimental and Molecular Therapeutics
Session Title: Signal Transduction Inhibitors
Location: Poster Section 28

TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis. Kline et al.
Abstract Number: 2942
Presentation Time: Tuesday Apr 21, 2015 8:00 AM - noon
Session Category: Molecular and Cellular Biology
Session Title: Cell Death Therapies 1
Location: Poster Section 2

ONC201/TIC10 targets colorectal cancer stem cells and bulk tumor cells via an Akt-Foxo3a-TRAIL-dependent mechanism. Prabhu et al.
Abstract Number: 4241
Presentation Time: Tuesday Apr 21, 2015 1:00 PM - 5:00 PM
Session Category: Tumor Biology
Session Title: Therapeutics Targeting Cancer Stem Cells
Location: Poster Section 21

In vitro efficacy profiling of ONC201 in cancer cells reveals sensitivity pattern that is consistent with ER stress response. Allen et al.
Abstract Number: 4475
Presentation Time: Tuesday Apr 21, 2015 1:00 PM - 5:00 PM
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Targets 2
Location: Poster Section 31

ONC201 is non-toxic at efficacious doses in vitro and in vivo. Allen et al.
Abstract Number: 4479
Presentation Time: Tuesday Apr 21, 2015 1:00 PM - 5:00 PM
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Targets 2
Location: Poster Section 31

Cytotoxicity, Biochemical Activity, and Structural Analysis of ONC201 Clinical Material and Comparisons to a Biologically Inactive Isomer. Wagner et al.
Abstract Number: 4499
Presentation Time: Tuesday Apr 21, 2015 1:00 PM - 5:00 PM
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Targets 2
Location: Poster Section 31

ONC201/TIC10 is effective as a monoagent and synergizes with chemotherapy to induce cell death in non-Hodgkin’s lymphoma. Talekar et al.
Abstract Number: 5387
Presentation Time: Wednesday Apr 22, 2015 8:00 AM - noon
Session Category: Experimental and Molecular Therapeutics
Session Title: Histone Deacetylase Inhibitors, Methyltransferase Inhibitors, and Other Targets
Location: Poster Section 29

About Oncoceutics

Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The first lead compound to result from this program is ONC201, a small molecule drug with a unique mechanism of action that causes significant anti-tumor activity in a variety of types of human cancer. The Company is currently enrolling patients in clinical trials of ONC201, which began in January 2015, following acceptance by the U.S. Food and Drug Administration of the Company’s Investigational New Drug (IND) application for ONC201 in 2014. Oncoceutics and collaborative groups have received approximately $5 million in grants over the last two years from the National Institutes of Health, the Pennsylvania Department of Health, and The Musella Foundation, and the company has leveraged additional funding from academic medical research partners that support multiple Phase I/II Clinical trials.

Visit Oncoceutics or contact Rohinton Tarapore for more information

Help employers find you! Check out all the jobs and post your resume.

Back to news